vs
Side-by-side financial comparison of Expensify, Inc. (EXFY) and IRONWOOD PHARMACEUTICALS INC (IRWD). Click either name above to swap in a different company.
IRONWOOD PHARMACEUTICALS INC is the larger business by last-quarter revenue ($47.7M vs $35.2M, roughly 1.4× Expensify, Inc.). On growth, Expensify, Inc. posted the faster year-over-year revenue change (-4.9% vs -47.3%). Over the past eight quarters, Expensify, Inc.'s revenue compounded faster (2.4% CAGR vs -20.2%).
Expensify, Inc. is a software company that develops an expense management system for personal and business use. Expensify also offers a business credit card called the Expensify Card.
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
EXFY vs IRWD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $35.2M | $47.7M |
| Net Profit | — | $-2.3M |
| Gross Margin | 49.2% | — |
| Operating Margin | -11.2% | 14.3% |
| Net Margin | — | -4.8% |
| Revenue YoY | -4.9% | -47.3% |
| Net Profit YoY | — | -200.9% |
| EPS (diluted) | $-0.07 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $35.2M | $47.7M | ||
| Q3 25 | $35.1M | $122.1M | ||
| Q2 25 | $35.8M | $85.2M | ||
| Q1 25 | $36.1M | $41.1M | ||
| Q4 24 | $37.0M | $90.5M | ||
| Q3 24 | $35.4M | $91.6M | ||
| Q2 24 | $33.3M | $94.4M | ||
| Q1 24 | $33.5M | $74.9M |
| Q4 25 | — | $-2.3M | ||
| Q3 25 | $-2.3M | $40.1M | ||
| Q2 25 | $-8.8M | $23.6M | ||
| Q1 25 | $-3.2M | $-37.4M | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | $-2.2M | $3.6M | ||
| Q2 24 | $-2.8M | $-860.0K | ||
| Q1 24 | $-3.8M | $-4.2M |
| Q4 25 | 49.2% | — | ||
| Q3 25 | 49.6% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 50.6% | — | ||
| Q4 24 | 51.0% | — | ||
| Q3 24 | 51.6% | — | ||
| Q2 24 | 56.9% | — | ||
| Q1 24 | 56.5% | — |
| Q4 25 | -11.2% | 14.3% | ||
| Q3 25 | -6.4% | 61.8% | ||
| Q2 25 | -28.9% | 53.2% | ||
| Q1 25 | -4.1% | -70.7% | ||
| Q4 24 | 1.3% | 34.8% | ||
| Q3 24 | 0.8% | 28.0% | ||
| Q2 24 | 0.7% | 26.5% | ||
| Q1 24 | -5.3% | 14.7% |
| Q4 25 | — | -4.8% | ||
| Q3 25 | -6.6% | 32.8% | ||
| Q2 25 | -24.6% | 27.7% | ||
| Q1 25 | -8.8% | -90.9% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | -6.2% | 4.0% | ||
| Q2 24 | -8.3% | -0.9% | ||
| Q1 24 | -11.3% | -5.6% |
| Q4 25 | $-0.07 | $0.01 | ||
| Q3 25 | $-0.03 | $0.23 | ||
| Q2 25 | $-0.10 | $0.14 | ||
| Q1 25 | $-0.03 | $-0.23 | ||
| Q4 24 | $-0.03 | $0.03 | ||
| Q3 24 | $-0.02 | $0.02 | ||
| Q2 24 | $-0.03 | $-0.01 | ||
| Q1 24 | $-0.04 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.1M | $215.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $132.7M | $-261.8M |
| Total Assets | $186.0M | $396.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.1M | $215.5M | ||
| Q3 25 | $61.5M | $140.4M | ||
| Q2 25 | $60.5M | $92.9M | ||
| Q1 25 | $59.6M | $108.5M | ||
| Q4 24 | $48.8M | $88.6M | ||
| Q3 24 | $39.2M | $88.2M | ||
| Q2 24 | $53.2M | $105.5M | ||
| Q1 24 | $49.3M | $121.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $199.5M | ||
| Q2 25 | — | $199.3M | ||
| Q1 25 | — | $199.2M | ||
| Q4 24 | — | $199.0M | ||
| Q3 24 | — | $198.8M | ||
| Q2 24 | — | $198.6M | ||
| Q1 24 | — | $398.3M |
| Q4 25 | $132.7M | $-261.8M | ||
| Q3 25 | $135.7M | $-264.2M | ||
| Q2 25 | $131.8M | $-308.2M | ||
| Q1 25 | $134.7M | $-334.1M | ||
| Q4 24 | $128.2M | $-301.3M | ||
| Q3 24 | $119.9M | $-311.3M | ||
| Q2 24 | $114.0M | $-321.7M | ||
| Q1 24 | $106.5M | $-330.5M |
| Q4 25 | $186.0M | $396.9M | ||
| Q3 25 | $186.8M | $396.1M | ||
| Q2 25 | $187.1M | $342.9M | ||
| Q1 25 | $189.2M | $327.2M | ||
| Q4 24 | $173.7M | $350.9M | ||
| Q3 24 | $176.2M | $389.5M | ||
| Q2 24 | $192.9M | $395.6M | ||
| Q1 24 | $184.8M | $438.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.2M | $74.6M |
| Free Cash FlowOCF − Capex | — | $74.6M |
| FCF MarginFCF / Revenue | — | 156.3% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $127.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.2M | $74.6M | ||
| Q3 25 | $4.2M | $47.6M | ||
| Q2 25 | $8.9M | $-15.1M | ||
| Q1 25 | $4.8M | $20.0M | ||
| Q4 24 | $7.4M | $15.2M | ||
| Q3 24 | $3.7M | $9.9M | ||
| Q2 24 | $9.3M | $33.5M | ||
| Q1 24 | $3.5M | $45.0M |
| Q4 25 | — | $74.6M | ||
| Q3 25 | — | $47.6M | ||
| Q2 25 | — | $-15.1M | ||
| Q1 25 | — | $19.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $9.9M | ||
| Q2 24 | — | $33.4M | ||
| Q1 24 | — | $44.9M |
| Q4 25 | — | 156.3% | ||
| Q3 25 | — | 39.0% | ||
| Q2 25 | — | -17.7% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.8% | ||
| Q2 24 | — | 35.4% | ||
| Q1 24 | — | 60.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.1% | ||
| Q1 24 | 0.0% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.19× | ||
| Q2 25 | — | -0.64× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.74× | ||
| Q3 24 | — | 2.71× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
